GHRP-6 Peptide: Mechanism, Ghrelin Receptor & Research Overview
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide studied as a ghrelin receptor agonist, distinct in structure and pathway from Growth Hormone Releasing Hormone (GHRH). Research spans growth hormone/IGF-1 signaling, wound healing, antifibrotic liver studies, and broader cytoprotective effects. This article organizes GHRP-6's structure, proposed mechanism, and evidence base by research category.
Key Facts at a Glance
| Property | Detail |
|---|---|
| Classification | Synthetic hexapeptide, Growth Hormone Secretagogue (GHS) family |
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ |
| Molecular formula | C46H56N12O6 |
| Molecular weight | ~873 g/mol |
| CAS number | 87616-84-0 |
| Primary receptor target | Ghrelin receptor (GHS-R), at the hypothalamic and pituitary level |
| Structural relationship to GHRH | None — GHRP-6 is structurally unrelated to Growth Hormone Releasing Hormone despite a related downstream effect |
| Evidence type | Primarily animal research (rodent models); some research spans several decades of study |
What Is GHRP-6?
GHRP-6 is a synthetic hexapeptide derived from met-enkephalin research, composed of a mix of L- and D-configured amino acids: L-Histidine, D-Tryptophan, L-Alanine, L-Tryptophan, D-Phenylalanine, and L-Lysine. It belongs to the Growth Hormone Secretagogue (GHS) family — compounds studied for their ability to stimulate release of another hormone, in this case growth hormone (GH).
Despite its name, GHRP-6 shares no structural similarity with Growth Hormone Releasing Hormone (GHRH). Instead, research indicates it acts through a separate receptor system tied to ghrelin signaling. Studies have also identified GHRP-6 receptor activity in peripheral tissues including the adrenal glands, heart, testis, ovary, skeletal muscle, and lung — suggesting research relevance beyond the pituitary axis.
GHRP-6 vs. GHRH: How They Differ
| Feature | GHRP-6 | GHRH |
|---|---|---|
| Structural class | Synthetic hexapeptide, GHS family | Native hypothalamic releasing hormone |
| Receptor targeted | Ghrelin receptor (GHS-R) | GHRH receptor |
| Structural relationship | Unrelated to GHRH structurally | N/A (native hormone) |
| Downstream effect studied | GH release, IGF-1 production, ghrelin-mimetic effects | GH release via its own dedicated pathway |
Mechanism of Action: Ghrelin Receptor Pathway
Animal research suggests GHRP-6 stimulates growth hormone release by acting as a ghrelin receptor agonist at the hypothalamic and pituitary level, distinct from the GHRH signaling pathway.
- GHRP-6 binds to the ghrelin receptor (GHS-R), mimicking the action of ghrelin, the endogenous "hunger hormone."
- Receptor activation at the hypothalamic/pituitary level signals increased growth hormone (GH) production and release.
- In response to elevated GH, the liver is believed to increase production of insulin-like growth factor-1 (IGF-1).
- IGF-1 is proposed to support cell proliferation and reduce cell death (apoptosis) in various tissue research models.
Research Findings by Area
| Research Area | Reported Findings | Evidence Level |
|---|---|---|
| Wound healing | Reduced wound inflammation, accelerated closure, improved aesthetic outcome in rat models | Animal research |
| Liver fibrosis | Prevention of fibrotic induration and reduction of accumulated fibrotic material in a rat cirrhosis model | Animal research |
| Cytoprotection (cardiac/extracardiac) | Antiapoptotic effects reported in ischemia/reperfusion research models | Animal research |
| Muscle protein synthesis | Associated with increased GH/IGF-1 signaling linked to anabolic activity | Animal/mechanistic research |
| Fat metabolism | Proposed association with improved metabolic rate in research models | Preliminary/mechanistic research |
| Tissue/collagen support | Speculative association with collagen production and tissue repair capacity | Early-stage/speculative |
Wound Healing Research in Detail
In rat models using clean, full-thickness controlled wounds, GHRP-6 was associated with changes in extracellular matrix protein accumulation, attenuated wound inflammation, and improved aesthetic healing outcomes. Proposed contributing mechanisms include:
- Reduced immunoinflammatory mediator and effector cell activity at the wound site
- Decreased expression of fibrosis-inducing cytokines, modulating fibroblast response to injury
- Inhibition of NF-κB activity, a pathway associated with pro-inflammatory cytokine expression, with GHRP-6 also proposed to act as a chemokine receptor antagonist in this context
Researchers noted these mechanisms did not appear to interfere with angiogenic repopulation or reepithelialization — two processes essential to normal wound healing — suggesting the anti-inflammatory effects were not broadly immunosuppressive in these models.
Liver Fibrosis Research in Detail
In a rat model of liver cirrhosis, GHRP-6 exposure was associated with prevention of parenchymal fibrotic induration in more than 85% of the study cohort, with removal of previously accumulated fibrotic material observed in 75% of subjects. Microarray gene expression analysis in this research also indicated modulation of genes associated with redox metabolism following GHRP-6 exposure.
GHRP-6 vs. Ipamorelin: Comparison Table
| Feature | GHRP-6 | Ipamorelin |
|---|---|---|
| Receptor mechanism | Ghrelin receptor (GHS-R) agonist | Ghrelin receptor (GHS-R) agonist |
| Reported ghrelin/hunger-related effects | Associated with increased appetite in research models | Reported to have a more selective GH-release profile with less pronounced appetite effect |
| Non-GH research interest | Extensive: wound healing, antifibrotic, cytoprotective research | Primarily focused on GH/IGF-1 axis research |
Storage and Stability
| Condition | Recommendation |
|---|---|
| Lyophilized form | Store frozen (-20°C) for long-term stability |
| Reconstituted solution | Refrigerate (2–8°C); use within the research protocol's defined window |
| Light exposure | Store protected from light |
| Handling | Avoid repeated freeze-thaw cycles to preserve peptide integrity |
Frequently Asked Questions
What is GHRP-6 used for in research?
GHRP-6 is studied for its ability to stimulate growth hormone release via the ghrelin receptor, along with broader research interest in wound healing, antifibrotic liver effects, and cytoprotection.
Is GHRP-6 related to GHRH?
No. Despite the similar naming convention, GHRP-6 shares no structural similarity with Growth Hormone Releasing Hormone and acts through a separate receptor pathway (the ghrelin receptor).
What receptor does GHRP-6 activate?
GHRP-6 acts as an agonist at the ghrelin receptor (GHS-R), primarily studied at the hypothalamic and pituitary level.
Does GHRP-6 increase IGF-1?
GHRP-6-stimulated GH release leads to increased hepatic production of IGF-1, a growth factor associated with cell proliferation and reduced cell death.
What is the amino acid sequence of GHRP-6?
His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, a hexapeptide combining both L- and D-configured amino acids.
Has GHRP-6 been studied for wound healing?
Yes. In rat models using controlled full-thickness wounds, GHRP-6 was associated with reduced inflammation, accelerated wound closure, and improved aesthetic healing outcomes, without apparent interference with normal repair processes like reepithelialization.
What did the liver cirrhosis research find?
In a rat model of liver cirrhosis, GHRP-6 was associated with prevention of fibrotic induration in over 85% of subjects and reduction of existing fibrotic material in 75% of subjects.
Does GHRP-6 affect appetite?
Because GHRP-6 mimics ghrelin, the "hunger hormone," research models have associated it with appetite stimulation, a known characteristic of ghrelin receptor agonists.
How does GHRP-6 compare to Ipamorelin?
Both act on the ghrelin receptor, but GHRP-6 has a more pronounced association with appetite stimulation and a broader non-GH research profile (wound healing, antifibrotic effects), while Dragon Pharma Ipamorelin is generally studied for a more selective GH-release effect.
Key Takeaways
- GHRP-6 is a synthetic hexapeptide that stimulates growth hormone release via the ghrelin receptor, structurally and mechanistically distinct from GHRH.
- Its research profile extends well beyond the GH/IGF-1 axis, with notable animal data on wound healing, liver antifibrotic effects, and cytoprotection.
- Because it mimics ghrelin, GHRP-6 is also associated with appetite stimulation in research models — a key differentiator from more GH-selective secretagogues like Ipamorelin.
- Liver fibrosis research in rat models reported fibrotic prevention in over 85% of subjects and material reduction in 75%.
- Available evidence is primarily preclinical and animal-based; findings should not be interpreted as established human outcomes.
- Researchers looking for a peptide for sale should ensure GHRP-6 is sourced as research-grade material from reputable suppliers and used exclusively for laboratory research purposes.
Articles
BPC-157 is a stable synthetic peptide developed from a naturally occurring protective compound found in human gastric juice, studied for reparative effects that extend well beyond the digestive tract.
This is top Dragon Pharma Steroids
Steroids Half-Lifes, oral and injectables. Know when to start PCT according to this list.
Customer Reviews
Please leave your review on products or service below.
Thank you beforehand.